Terumo
Terumo Corporation, a leading global medical technology company headquartered in Japan, has been at the forefront of healthcare innovation since its founding in 1921. With a strong presence in regions such as Europe, Asia, and the Americas, Terumo operates primarily within the medical devices industry, focusing on areas like vascular intervention, blood management, and surgical products. Renowned for its commitment to quality and safety, Terumo offers a diverse range of core products, including advanced catheter systems, blood collection devices, and infusion systems. These products are distinguished by their cutting-edge technology and user-centric design, ensuring optimal performance in clinical settings. As a trusted partner in healthcare, Terumo has achieved significant milestones, including numerous certifications and recognitions for excellence in medical technology, solidifying its position as a key player in the global market.
DitchCarbon Score
How does Terumo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Terumo's score of 58 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Terumo's reported carbon emissions
In 2023, Terumo Corporation reported total greenhouse gas emissions of approximately 206,031,000 kg CO2e globally, with 64,123,000 kg CO2e from Scope 1 and 141,908,000 kg CO2e from Scope 2. In Japan, the company emitted about 42,313,000 kg CO2e in Scope 1 and approximately 50,329,000 kg CO2e in Scope 2, totalling around 92,643,000 kg CO2e for these scopes. Terumo has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 30% by 2030 and 80% by 2050, using 2018 as the base year. Additionally, the company has committed to reducing Scope 3 emissions by 60% per unit of revenue over the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit temperature rise to 1.5°C. Furthermore, Terumo aims to achieve carbon neutrality by 2040 for both Scope 1 and Scope 2 emissions. The company is actively working towards these goals, reflecting its commitment to sustainability and environmental responsibility in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Terumo is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
